暂无分享,去创建一个
Jiuyong Li | Thuc Duy Le | Lin Liu | Vu Viet Hoang Pham | Cameron Bracken | Gregory Goodall | Jiuyong Li | T. Le | Lin Liu | V. V. H. Pham | C. Bracken | G. Goodall
[1] Sergey Brin,et al. The Anatomy of a Large-Scale Hypertextual Web Search Engine , 1998, Comput. Networks.
[2] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[3] Rajeev Motwani,et al. The PageRank Citation Ranking : Bringing Order to the Web , 1999, WWW 1999.
[4] Philippe Dessen,et al. Atlas of Genetics and Cytogenetics in Oncology and Haematology, an Interactive Database , 2000, Nucleic Acids Res..
[5] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[6] Marina Pollán,et al. Positive correlation between the expression of X‐chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer , 2006, Journal of cellular biochemistry.
[7] T. Hampton,et al. The Cancer Genome Atlas , 2020, Indian Journal of Medical and Paediatric Oncology.
[8] A. Mele,et al. Ago HITS-CLIP decodes miRNA-mRNA interaction maps , 2009, Nature.
[9] Scott B. Dewell,et al. Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP , 2010, Cell.
[10] W. Linehan,et al. The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.
[11] Mingming Jia,et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..
[12] D. Pe’er,et al. An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.
[13] Ming Lu,et al. TransmiR: a transcription factor–microRNA regulation database , 2009, Nucleic Acids Res..
[14] C. Sander,et al. Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.
[15] A. Vinayagam,et al. A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction , 2011, Science Signaling.
[16] Ling Lin,et al. PathScan: a tool for discerning mutational significance in groups of putative cancer genes , 2011, Bioinform..
[17] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[18] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[19] A. Gonzalez-Perez,et al. Functional impact bias reveals cancer drivers , 2012, Nucleic acids research.
[20] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[21] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[22] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[23] Doron Betel,et al. Genome-wide identification of miRNA targets by PAR-CLIP. , 2012, Methods.
[24] A. Bashashati,et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.
[25] Ö. Türeci,et al. NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells , 2013, BMC Cancer.
[26] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[27] Joshua F. McMichael,et al. DGIdb - Mining the druggable genome , 2013, Nature Methods.
[28] D. Wheeler,et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif , 2013, Nature Communications.
[29] David Haussler,et al. Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE) , 2013, Bioinform..
[30] David S. Goodsell,et al. The RCSB Protein Data Bank: new resources for research and education , 2012, Nucleic Acids Res..
[31] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[32] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[33] David Tamborero,et al. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..
[34] Gary D Bader,et al. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers , 2013 .
[35] Shi-Hua Zhang,et al. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data , 2013, BMC Systems Biology.
[36] C. Sander,et al. Genome-wide analysis of non-coding regulatory mutations in cancer , 2014, Nature Genetics.
[37] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[38] J. P. Hou,et al. DawnRank: discovering personalized driver genes in cancer , 2014, Genome Medicine.
[39] Zhuowen Tu,et al. Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.
[40] R. C. Poulos,et al. The search for cis-regulatory driver mutations in cancer genomes , 2015, Oncotarget.
[41] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[42] CoMEt: A Statistical Approach to Identify Combinations of Mutually Exclusive Alterations in Cancer , 2015, RECOMB.
[43] A. Chella,et al. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers , 2015, Proceedings of the National Academy of Sciences.
[44] Zhongming Zhao,et al. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach* , 2015, Molecular & Cellular Proteomics.
[45] Niko Beerenwinkel,et al. Identification of Constrained Cancer Driver Genes Based on Mutation Timing , 2015, PLoS Comput. Biol..
[46] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[47] Adam Godzik,et al. Cancer3D: understanding cancer mutations through protein structures , 2014, Nucleic Acids Res..
[48] Hsien-Da Huang,et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..
[49] A. Gonzalez-Perez,et al. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations , 2016, Genome Biology.
[50] Ananya Gupta,et al. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK–eIF2α–ATF4 signalling in breast cancer , 2016, Oncogene.
[51] K. Kinzler,et al. Evaluating the evaluation of cancer driver genes , 2016, Proceedings of the National Academy of Sciences.
[52] A. Barabasi,et al. Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets , 2015, Proceedings of the National Academy of Sciences.
[53] Francesca D. Ciccarelli,et al. NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings , 2015, Nucleic Acids Res..
[54] Li Ding,et al. Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.
[55] Allison P. Heath,et al. Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.
[56] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[57] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[58] C. Sander,et al. 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.
[59] C. Croce,et al. miR-579-3p controls melanoma progression and resistance to target therapy , 2016, Proceedings of the National Academy of Sciences.
[60] Jiuyong Li,et al. CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization , 2017, Bioinform..
[61] M. Rubin,et al. Non-coding genetic variation in cancer. , 2017, Current opinion in systems biology.
[62] Emanuela M. Ghia,et al. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia , 2017, Proceedings of the National Academy of Sciences.
[63] Abstract 4494: Tumor suppressive role of ZFP36L1 by suppressing HIF1α and Cyclin D1 in bladder and breast cancer , 2017 .
[64] Teresa M. Przytycka,et al. WeSME: uncovering mutual exclusivity of cancer drivers and beyond , 2016, Bioinform..
[65] Niko Beerenwinkel,et al. Computational approaches for the identification of cancer genes and pathways , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.
[66] Kaitlin G Scheer,et al. Post-transcriptional control of EMT is coordinated through combinatorial targeting by multiple microRNAs , 2017, bioRxiv.
[67] Liming Xu,et al. Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression , 2016, Technology in cancer research & treatment.
[68] Fabio Vandin. Computational Methods for Characterizing Cancer Mutational Heterogeneity , 2017, Front. Genet..
[69] Nicholas A. Sinnott-Armstrong,et al. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival , 2017, npj Genomic Medicine.
[70] Lei Zhang,et al. Discovering personalized driver mutation profiles of single samples in cancer by network control strategy , 2018, Bioinform..
[71] Ruth Nussinov,et al. Precision medicine review: rare driver mutations and their biophysical classification , 2019, Biophysical Reviews.
[72] Xiaowei Wang,et al. OncomiR: an online resource for exploring pan-cancer microRNA dysregulation , 2018, Bioinform..
[73] Junpeng Zhang,et al. Identifying miRNA-mRNA regulatory relationships in breast cancer with invariant causal prediction , 2018, BMC Bioinformatics.
[74] Tao Zeng,et al. A novel network control model for identifying personalized driver genes in cancer , 2019, PLoS Comput. Biol..
[75] Jiuyong Li,et al. CBNA: A control theory based method for identifying coding and non-coding cancer drivers , 2019, PLoS Comput. Biol..
[76] X. Hua,et al. DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies , 2019, Nucleic acids research.
[77] Ruth Nussinov,et al. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers , 2019, PLoS Comput. Biol..
[78] R. Nussinov,et al. Why Are Some Driver Mutations Rare? , 2019, Trends in pharmacological sciences.
[79] Jiuyong Li,et al. Identifying miRNA synergism using multiple-intervention causal inference , 2019, BMC Bioinformatics.
[80] Shaoyong Lu,et al. AlloDriver: a method for the identification and analysis of cancer driver targets , 2019, Nucleic Acids Res..
[81] Ruth Nussinov,et al. Autoinhibition can identify rare driver mutations and advise pharmacology , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] Vu V H Pham,et al. DriverGroup: A novel method for identifying driver gene groups , 2020, bioRxiv.
[83] J. Downing,et al. CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data , 2020, Genome Biology.
[84] Vu V H Pham,et al. pDriver : A novel method for unravelling personalised coding and miRNA cancer drivers , 2020, bioRxiv.